Prostate cancer relevant antigens and enzymes for targeted drug delivery

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 118-132

  Barve, Ashutosh ^a   Jin, Wei ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

HER2; Prostate cancer; PSA; PSCA; PSMA; Tumor microenvironment

Indexed keywords

ANTIGENS; CELLS; CHEMOTHERAPY; DESIGN; DRUG DELIVERY; ENZYMES; NUCLEIC ACIDS; TUMORS;

HER2; PROSTATE CANCERS; PSA; PSCA; PSMA; TUMOR MICROENVIRONMENT;

DISEASES;

ANTIGEN; CATHEPSIN; CD147 ANTIGEN; DRUG CARRIER; ENZYME; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR LIKE 7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GASTRIN RELEASING PEPTIDE RECEPTOR; HEAT SHOCK PROTEIN; HORMONE RECEPTOR; LIGAND; LUTEINIZING HORMONE RELEASING HORMONE RECEPTOR; MATRIX METALLOPROTEINASE; MUCIN 1; NEUROMEDIN B; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; ENZYMOLOGY; IMMUNOLOGY; MALE; METABOLISM; PROSTATE TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902241291     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.035     Document Type: Review

References (269)

1. N.J. Mabjeesh, H. Zhong, and J.W. Simons Gene therapy of prostate cancer: current and future directions Endocr. Relat. Cancer 9 2 2002 115 139
2. J.W. Moul, H. Wu, L. Sun, D.G. McLeod, C. Amling, T. Donahue, L. Kusuda, W. Sexton, K. O'Reilly, J. Hernandez, A. Chung, and D. Soderdahl Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J. Urol. 171 3 2004 1141 1147
3. J.W. Moul The evolving definition of advanced prostate cancer Rev. Urol. 6 Suppl. 8 2004 S10 S17
4. H.J. Ananias, M.C. van den Heuvel, W. Helfrich, and I.J. de Jong Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer Prostate 69 10 2009 1101 1108
5. M.I. Davis, M.J. Bennett, L.M. Thomas, and P.J. Bjorkman Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase Proc. Natl. Acad. Sci. U. S. A. 102 17 2005 5981 5986
6. J.R. Mesters, C. Barinka, W. Li, T. Tsukamoto, P. Majer, B.S. Slusher, J. Konvalinka, and R. Hilgenfeld Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer EMBO J. 25 6 2006 1375 1384
7. Q.L. Tang, and M.Y. Yao Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer Zhonghua Nan Ke Xue 14 1 2008 79 82
8. J.T. Bukrinsky, M.J. Bjerrum, and A. Kadziola Native carboxypeptidase A in a new crystal environment reveals a different conformation of the important tyrosine 248 Biochemistry 37 47 1998 16555 16564
9. D.G. Bostwick, A. Pacelli, M. Blute, P. Roche, and G.P. Murphy Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases Cancer 82 11 1998 2256 2261
10. G.L. Wright Jr., C. Haley, M.L. Beckett, and P.F. Schellhammer Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues Urol. Oncol. 1 1 1995 18 28
11. R.S. Israeli, C.T. Powell, J.G. Corr, W.R. Fair, and W.D. Heston Expression of the prostate-specific membrane antigen Cancer Res. 54 7 1994 1807 1811
12. G.L. Wright Jr., B.M. Grob, C. Haley, K. Grossman, K. Newhall, D. Petrylak, J. Troyer, A. Konchuba, P.F. Schellhammer, and R. Moriarty Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 2 1996 326 334
13. S.D. Sweat, A. Pacelli, G.P. Murphy, and D.G. Bostwick Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 4 1998 637 640
14. J.K. Troyer, M.L. Beckett, and G.L. Wright Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids Int. J. Cancer 62 5 1995 552 558
15. A. Ghosh, and W.D. Heston Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 91 3 2004 528 539
16. R.L. Sokoloff, K.C. Norton, C.L. Gasior, K.M. Marker, and L.S. Grauer A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine Prostate 43 2 2000 150 157
17. D.M. Nanus, M.I. Milowsky, L. Kostakoglu, P.M. Smith-Jones, S. Vallabahajosula, S.J. Goldsmith, and N.H. Bander Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen J. Urol. 170 6 Pt 2 2003 S84 S88 (discussion S88-9)
18. S.S. Chang, V.E. Reuter, W.D. Heston, N.H. Bander, L.S. Grauer, and P.B. Gaudin Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 59 13 1999 3192 3198
19. J.S. Ross, C.E. Sheehan, H.A. Fisher, R.P. Kaufman Jr., P. Kaur, K. Gray, I. Webb, G.S. Gray, R. Mosher, and B.V. Kallakury Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer Clin. Cancer Res. 9 17 2003 6357 6362
20. U. Elsasser-Beile, P. Buhler, and P. Wolf Targeted therapies for prostate cancer against the prostate specific membrane antigen Curr. Drug Targets 10 2 2009 118 125
21. T.P. Thomas, A.K. Patri, A. Myc, M.T. Myaing, J.Y. Ye, T.B. Norris, and J.R. Baker Jr. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles Biomacromolecules 5 6 2004 2269 2274
22. S. Aggarwal, P. Singh, O. Topaloglu, J.T. Isaacs, and S.R. Denmeade A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity Cancer Res. 66 18 2006 9171 9177
23. B. Qin, W. Tai, R.S. Shukla, and K. Cheng Identification of a LNCaP-specific binding peptide using phage display Pharm. Res. 28 10 2011 2422 2434
24. W. Xu, I.A. Siddiqui, M. Nihal, S. Pilla, K. Rosenthal, H. Mukhtar, and S. Gong Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer Biomaterials 34 21 2013 5244 5253
25. P.M. Smith-Jones, S. Vallabhajosula, V. Navarro, D. Bastidas, S.J. Goldsmith, and N.H. Bander Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor J. Nucl. Med. 44 4 2003 610 617
26. S.S. Chang Overview of prostate-specific membrane antigen Rev. Urol. 6 Suppl. 10 2004 S13 S18
27. V. Baum, P. Buhler, D. Gierschner, D. Herchenbach, G.J. Fiala, W.W. Schamel, P. Wolf, and U. Elsasser-Beile Antitumor activities of PSMAxCD3 diabodies by redirected T-cell lysis of prostate cancer cells Immunotherapy 5 1 2013 27 38
28. P. Buhler, P. Wolf, D. Gierschner, I. Schaber, A. Katzenwadel, W. Schultze-Seemann, U. Wetterauer, M. Tacke, M. Swamy, W.W. Schamel, and U. Elsasser-Beile A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells Cancer Immunol. Immunother. 57 1 2008 43 52
29. R.J. Durso, S. Andjelic, J.P. Gardner, D.J. Margitich, G.P. Donovan, R.R. Arrigale, X. Wang, M.F. Maughan, T.L. Talarico, R.A. Olmsted, W.D. Heston, P.J. Maddon, and W.C. Olson A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses Clin. Cancer Res. 13 13 2007 3999 4008
30. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group J. Urol. 159 6 1998 2041 2046
31. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence J. Urol. 152 5 Pt 1 1994 1490 1495
32. N. Deb, M. Goris, K. Trisler, S. Fowler, J. Saal, S. Ning, M. Becker, C. Marquez, and S. Knox Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody Clin. Cancer Res. 2 8 1996 1289 1297
33. D. Kahn, J.C. Austin, R.T. Maguire, S.J. Miller, J. Gerstbrein, and R.D. Williams A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy Cancer Biother. Radiopharm. 14 2 1999 99 111
34. U. Elsasser-Beile, G. Reischl, S. Wiehr, P. Buhler, P. Wolf, K. Alt, J. Shively, M.S. Judenhofer, H.J. Machulla, and B.J. Pichler PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen J. Nucl. Med. 50 4 2009 606 611
35. P. Wolf, K. Alt, P. Buhler, A. Katzenwadel, U. Wetterauer, M. Tacke, and U. Elsasser-Beile Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice Prostate 68 2 2008 129 138
36. M. Behe, K. Alt, F. Deininger, P. Buhler, U. Wetterauer, W.A. Weber, U. Elsasser-Beile, and P. Wolf In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer In Vivo. 25 1 2011 55 59
37. M.R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M.J. Curcio, G. Sgouros, A.M. Ballangrud, W.H. Yang, R.D. Finn, V. Pellegrini, M.W. Geerlings Jr., M. Lee, M.W. Brechbiel, N.H. Bander, C. Cordon-Cardo, and D.A. Scheinberg An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer Cancer Res. 60 21 2000 6095 6100
38. S. Vallabhajosula, P.M. Smith-Jones, V. Navarro, S.J. Goldsmith, and N.H. Bander Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice Prostate 58 2 2004 145 155
39. S.A. Kularatne, K. Wang, H.K. Santhapuram, and P.S. Low Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand Mol. Pharm. 6 3 2009 780 789
40. M.D. Henry, S. Wen, M.D. Silva, S. Chandra, M. Milton, and P.J. Worland A prostate-specific membrane antigen-targeted monoclonal antibody- chemotherapeutic conjugate designed for the treatment of prostate cancer Cancer Res. 64 21 2004 7995 8001
41. K. Kuroda, H. Liu, S. Kim, M. Guo, V. Navarro, and N.H. Bander Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity Prostate. 70 12 2010 1286-94
42. P. Wolf, and U. Elsasser-Beile Pseudomonas exotoxin A: from virulence factor to anti-cancer agent Int. J. Med. Microbiol. 299 3 2009 161 176
43. P. Wolf, D. Gierschner, P. Buhler, U. Wetterauer, and U. Elsasser-Beile A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells Cancer Immunol. Immunother. 55 11 2006 1367 1373
44. Kularatne, S.A., C. Venkatesh, H.K. Santhapuram, K. Wang, B. Vaitilingam, W.A. Henne, and P.S. Low Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs J Med Chem. 53 21 2010 7767-77
45. Kim, E., Y. Jung, H. Choi, J. Yang, J.S. Suh, Y.M. Huh, K. Kim, and S. Haam, Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials. 31(16): p. 4592-9.
46. D. Ma, C.E. Hopf, A.D. Malewicz, G.P. Donovan, P.D. Senter, W.F. Goeckeler, P.J. Maddon, and W.C. Olson Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen Clin. Cancer Res. 12 8 2006 2591 2596
47. Zhao, Y., S. Duan, X. Zeng, C. Liu, N.M. Davies, B. Li, and M.L. Forrest, Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm. 9(6): p. 1705-16.
48. V. Sanna, G. Pintus, A.M. Roggio, S. Punzoni, A.M. Posadino, A. Arca, S. Marceddu, P. Bandiera, S. Uzzau, and M. Sechi Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells J. Med. Chem. 54 5 2011 1321 1332
49. S. Dhar, N. Kolishetti, S.J. Lippard, and O.C. Farokhzad Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo Proc. Natl. Acad. Sci. U. S. A. 108 5 2011 1850 1855
50. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, and S.J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U. S. A. 105 45 2008 17356 17361
51. J.S. Lam, J. Yamashiro, I.P. Shintaku, R.L. Vessella, R.B. Jenkins, S. Horvath, J.W. Said, and R.E. Reiter Prostate stem cell antigen is overexpressed in prostate cancer metastases Clin. Cancer Res. 11 7 2005 2591 2596
52. D.G. Tang, L. Patrawala, T. Calhoun, B. Bhatia, G. Choy, R. Schneider-Broussard, and C. Jeter Prostate cancer stem/progenitor cells: identification, characterization, and implications Mol. Carcinog. 46 1 2007 1 14
53. M. Antica, L. Wu, and R. Scollay Stem cell antigen 2 expression in adult and developing mice Immunol. Lett. 55 1 1997 47 51
54. B.J. Classon, and L. Coverdale Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins Proc. Natl. Acad. Sci. U. S. A. 91 12 1994 5296 5300
55. A.B. Raff, A. Gray, and W.M. Kast Prostate stem cell antigen: a prospective therapeutic and diagnostic target Cancer Lett. 277 2 2009 126 132
56. R.E. Reiter, Z. Gu, T. Watabe, G. Thomas, K. Szigeti, E. Davis, M. Wahl, S. Nisitani, J. Yamashiro, M.M. Le Beau, M. Loda, and O.N. Witte Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer Proc. Natl. Acad. Sci. U. S. A. 95 4 1998 1735 1740
57. J. Taeb, M. Asgari, M. Abolhasani, M.M. Farajollahi, and Z. Madjd Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients Pathol. Res. Pract. 210 1 2014 18 23
58. Z. Zhigang, and S. Wenlv Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer Jpn. J. Clin. Oncol. 34 7 2004 414 419
59. Z. Gu, G. Thomas, J. Yamashiro, I.P. Shintaku, F. Dorey, A. Raitano, O.N. Witte, J.W. Said, M. Loda, and R.E. Reiter Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer Oncogene 19 10 2000 1288 1296
60. X. Gao, Y. Luo, Y. Wang, J. Pang, C. Liao, H. Lu, and Y. Fang Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy Int. J. Nanomedicine 7 2012 4037 4051
61. Y. Ling, K. Wei, Y. Luo, X. Gao, and S. Zhong Dual docetaxel/ superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy Biomaterials. 32 29 2011 7139-50
62. J. Zhou, L. Huang, W. Wang, J. Pang, Y. Zou, X. Shuai, and X. Gao Prostate cancer targeted MRI nanoprobe based on superparamagnetic iron oxide and copolymer of poly(ethylene glycol) and polyethyleneimin Chin. Sci. Bull. 54 18 2009 3137 3146
63. Li, Y., P.J. Cozzi, and P.J. Russell Promising tumor-associated antigens for future prostate cancer therapy Med Res Rev. 30 1 2010 67 101
64. L. Garcia-Hernandez Mde, A. Gray, B. Hubby, O.J. Klinger, and W.M. Kast Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity Cancer Res. 68 3 2008 861 869
65. A.K. Thomas-Kaskel, R. Zeiser, R. Jochim, C. Robbel, W. Schultze-Seemann, C.F. Waller, and H. Veelken Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival Int. J. Cancer 119 10 2006 2428 2434
66. W. Tai, R. Mahato, and K. Cheng The role of HER2 in cancer therapy and targeted drug delivery J. Control. Release 146 3 2010 264 275
67. 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts Eur. J. Nucl. Med. Mol. Imaging 39 3 2012 481 492
68. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2 2001 127 137
69. D. Gioeli, S.B. Ficarro, J.J. Kwiek, D. Aaronson, M. Hancock, A.D. Catling, F.M. White, R.E. Christian, R.E. Settlage, J. Shabanowitz, D.F. Hunt, and M.J. Weber Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites J. Biol. Chem. 277 32 2002 29304 29314
70. N. Craft, Y. Shostak, M. Carey, and C.L. Sawyers A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nat. Med. 5 3 1999 280 285
71. Z. Culig, A. Hobisch, M.V. Cronauer, C. Radmayr, J. Trapman, A. Hittmair, G. Bartsch, and H. Klocker Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor Cancer Res. 54 20 1994 5474 5478
72. S. Minner, B. Jessen, L. Stiedenroth, E. Burandt, J. Kollermann, M. Mirlacher, A. Erbersdobler, C. Eichelberg, M. Fisch, T.H. Brummendorf, C. Bokemeyer, R. Simon, T. Steuber, M. Graefen, H. Huland, G. Sauter, and T. Schlomm Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer Clin. Cancer Res. 16 5 2010 1553 1560
73. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J. Clin. Oncol. 23 32 2005 8253 8261
74. A. So, M. Gleave, A. Hurtado-Col, and C. Nelson Mechanisms of the development of androgen independence in prostate cancer World J. Urol. 23 1 2005 1 9
75. S. Signoretti, R. Montironi, J. Manola, A. Altimari, C. Tam, G. Bubley, S. Balk, G. Thomas, I. Kaplan, L. Hlatky, P. Hahnfeldt, P. Kantoff, and M. Loda Her-2-neu expression and progression toward androgen independence in human prostate cancer J. Natl. Cancer Inst. 92 23 2000 1918 1925
76. A. Ziada, A. Barqawi, L.M. Glode, M. Varella-Garcia, F. Crighton, S. Majeski, M. Rosenblum, M. Kane, L. Chen, and E.D. Crawford The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 4 2004 332 337
77. D.B. Agus, H.I. Scher, B. Higgins, W.D. Fox, G. Heller, M. Fazzari, C. Cordon-Cardo, and D.W. Golde Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models Cancer Res. 59 19 1999 4761 4764
78. W. Tai, R.S. Shukla, B. Qin, B. Li, and K. Cheng Development of a peptide-drug conjugate for prostate cancer therapy Mol. Pharm. 8 3 2011 901 912
79. M. Shadidi, and M. Sioud Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells FASEB J. 17 2 2003 256 258
80. Z. Liu, J.H. Duan, Y.M. Song, J. Ma, F.D. Wang, X. Lu, and X.D. Yang Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro J. Transl. Med. 10 2012 148
81. J. Gao, K. Chen, Z. Miao, G. Ren, X. Chen, S.S. Gambhir, and Z. Cheng Affibody-based nanoprobes for HER2-expressing cell and tumor imaging Biomaterials 32 8 2011 2141 2148
82. F. Alexis, P. Basto, E. Levy-Nissenbaum, A.F. Radovic-Moreno, L. Zhang, E. Pridgen, A.Z. Wang, S.L. Marein, K. Westerhof, L.K. Molnar, and O.C. Farokhzad HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy ChemMedChem 3 12 2008 1839 1843
83. 1, the renaissance molecule J. Mammary Gland Biol. Neoplasia 6 3 2001 339 353
84. S. Yonezawa, M. Higashi, N. Yamada, S. Yokoyama, S. Kitamoto, S. Kitajima, and M. Goto Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application Pathol Int. 61 12 2011 697 716
85. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat. Rev. Cancer 9 12 2009 874 885
86. M.A. Hollingsworth, and B.J. Swanson Mucins in cancer: protection and control of the cell surface Nat. Rev. Cancer 4 1 2004 45 60
87. 1 carcinoma-associated antigen and beta-catenin Mol. Cell. Biol. 18 12 1998 7216 7224
88. 1 breast carcinoma-associated antigen and beta-catenin in cell adhesion J. Biol. Chem. 272 19 1997 12492 12494
89. 1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein Cancer Res. 55 18 1995 4000 4003
90. 1: a multifunctional cell surface component of reproductive tissue epithelia Reprod. Biol. Endocrinol. 2 2004 4
91. S.J. Gendler, and A.P. Spicer Epithelial mucin genes Annu. Rev. Physiol. 57 1995 607 634
92. 1: a target molecule for cancer therapy Cancer Biol. Ther. 6 4 2007 481 486
93. 1 oncoprotein is a druggable target in human prostate cancer cells Mol. Cancer Ther. 8 11 2009 3056 3065
94. 6 expression in the progression of prostate cancer Clin. Exp. Metastasis 22 7 2005 565 573
95. 1 expression in prostate carcinoma: correlation with grade and stage Mol. Urol. 3 3 1999 163 168
96. 1 in prostate cancer: relationship to clinical stage and prognosis Int. J. Urol. 12 7 2005 654 661
97. 4, in human prostate carcinomas Prostate 66 4 2006 421 429
98. E. van Bracht, S. Stolle, T.G. Hafmans, O.C. Boerman, E. Oosterwijk, T.H. van Kuppevelt, and W.F. Daamen Specific targeting of tumor cells by lyophilisomes functionalized with antibodies Eur. J. Pharm. Biopharm. 87 1 2014 80 89
99. 1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma Cancer Res. 58 19 1998 4324 4332
100. 1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro PLoS ONE 7 2 2012 e31970
101. 1-positive cancer cells in vitro PLoS ONE 6 9 2011 e24077
102. L. Tan, K.G. Neoh, E.T. Kang, W.S. Choe, and X. Su PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells Macromol Biosci. 11 10 2011 1331-5
103. 1-targeted peptide vaccine therapy in prostate cancer Expert. Opin. Biol. Ther. 7 11 2007 1723 1730
104. S. North, and C. Butts Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers Expert. Rev. Vaccines 4 3 2005 249 257
105. A.K. Nalla, B. Gorantla, C.S. Gondi, S.S. Lakka, and J.S. Rao Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells Cancer Gene Ther. 17 9 2010 599 613
106. M. Wang, D.W. Lowik, A.D. Miller, and M. Thanou Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles Bioconjug. Chem. 20 1 2009 32 40
107. P.A. Andreasen, L. Sottrup-Jensen, L. Kjoller, A. Nykjaer, S.K. Moestrup, C.M. Petersen, and J. Gliemann Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes FEBS Lett. 338 3 1994 239 245
108. H. Myohanen, and A. Vaheri Regulation and interactions in the activation of cell-associated plasminogen Cell. Mol. Life Sci. 61 22 2004 2840 2858
109. K. Dano, N. Behrendt, G. Hoyer-Hansen, M. Johnsen, L.R. Lund, M. Ploug, and J. Romer Plasminogen activation and cancer Thromb. Haemost. 93 4 2005 676 681
110. N. Behrendt The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling Biol. Chem. 385 2 2004 103 136
111. F. Blasi, and P. Carmeliet uPAR: a versatile signalling orchestrator Nat. Rev. Mol. Cell Biol. 3 12 2002 932 943
112. P.A. Andreasen, R. Egelund, and H.H. Petersen The plasminogen activation system in tumor growth, invasion, and metastasis Cell. Mol. Life Sci. 57 1 2000 25 40
113. S.M. Pulukuri, C.S. Gondi, S.S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J.S. Rao RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo J. Biol. Chem. 280 43 2005 36529 36540
114. K. Dass, A. Ahmad, A.S. Azmi, S.H. Sarkar, and F.H. Sarkar Evolving role of uPA/uPAR system in human cancers Cancer Treat. Rev. 34 2 2008 122 136
115. D. Gavrilov, O. Kenzior, M. Evans, R. Calaluce, and W.R. Folk Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers Eur. J. Cancer 37 8 2001 1033 1040
116. P.J. Cozzi, J. Wang, W. Delprado, M.C. Madigan, S. Fairy, P.J. Russell, and Y. Li Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer Hum. Pathol. 37 11 2006 1442 1451
117. Y. Li, and P.J. Cozzi Targeting uPA/uPAR in prostate cancer Cancer Treat. Rev. 33 6 2007 521 527
118. L. Yang, H.K. Sajja, Z. Cao, W. Qian, L. Bender, A.I. Marcus, M. Lipowska, W.C. Wood, and Y.A. Wang uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection Theranostics 4 1 2013 106 118
119. M. Persson, H. Liu, J. Madsen, Z. Cheng, and A. Kjaer First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts Nucl. Med. Biol. 40 5 2013 618 624
120. 64Cu-DOTA-AE105: implications for visualizing cancer invasion J. Nucl. Med. 53 1 2012 138 145
121. M. Ploug, S. Ostergaard, H. Gardsvoll, K. Kovalski, C. Holst-Hansen, A. Holm, L. Ossowski, and K. Dano Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation Biochemistry 40 40 2001 12157 12168
122. S.A. Rabbani, B. Ateeq, A. Arakelian, M.L. Valentino, D.E. Shaw, L.M. Dauffenbach, C.A. Kerfoot, and A.P. Mazar An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo Neoplasia 12 10 2010 778 788
123. G. Van Buren II, M.J. Gray, N.A. Dallas, L. Xia, S.J. Lim, F. Fan, A.P. Mazar, and L.M. Ellis Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver Cancer 115 14 2009 3360 3368
124. 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts Nucl. Med. Biol. 39 7 2012 962 969
125. Abdalla, M.O., P. Karna, H.K. Sajja, H. Mao, C. Yates, T. Turner, and R. Aneja Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy J Control Release. 149 3 2011 314-22
126. R. Markwalder, and J.C. Reubi Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Res. 59 5 1999 1152 1159
127. F. Hohla, and A.V. Schally Targeting gastrin releasing peptide receptors: new options for the therapy and diagnosis of cancer Cell Cycle 9 9 2010 1738 1741
128. R.T. Jensen, J.F. Battey, E.R. Spindel, and R.V. Benya International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states Pharmacol. Rev. 60 1 2008 1 42
129. D.B. Cornelio, R. Roesler, and G. Schwartsmann Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Oncol. 18 9 2007 1457 1466
130. M. Korner, B. Waser, R. Rehmann, and J.C. Reubi Early over-expression of GRP receptors in prostatic carcinogenesis Prostate 74 2 2014 217 224
131. J.C. Reubi, S. Wenger, J. Schmuckli-Maurer, J.C. Schaer, and M. Gugger Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14) Clin. Cancer Res. 8 4 2002 1139 1146
132. B. Sun, G. Halmos, A.V. Schally, X. Wang, and M. Martinez Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers Prostate 42 4 2000 295 303
133. M. de Visser, W.M. van Weerden, C.M. de Ridder, S. Reneman, M. Melis, E.P. Krenning, and M. de Jong Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts J. Nucl. Med. 48 1 2007 88 93
134. R.P. Schroeder, W.M. van Weerden, C. Bangma, E.P. Krenning, and M. de Jong Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues Methods 48 2 2009 200 204
135. C. Dubuc, R. Langlois, F. Benard, N. Cauchon, K. Klarskov, P. Tone, and J.E. van Lier Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate Bioorg. Med. Chem. Lett. 18 7 2008 2424 2427
136. Dumont, R.A., M. Tamma, F. Braun, S. Borkowski, J.C. Reubi, H. Maecke, W.A. Weber, and R. Mansi Targeted radiotherapy of prostate cancer with a gastrin-releasing Peptide receptor antagonist is effective as monotherapy and in combination with rapamycin J Nucl Med. 54 5 2013 762-9
137. Okarvi, S.M., and I. Al Jammaz Synthesis and evaluation of a technetium-99 m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors Nucl Med Biol. 37 3 2010 277-88
138. A. Accardo, G. Salsano, A. Morisco, M. Aurilio, A. Parisi, F. Maione, C. Cicala, D. Tesauro, L. Aloj, G. De Rosa, and G. Morelli Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent Int J Nanomedicine. 7 2012 2007-17
139. 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer Nucl. Med. Biol. 39 5 2012 609 616
140. 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer J. Nucl. Med. 52 3 2011 470 477
141. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors J. Nucl. Med. 52 2 2011 270 278
142. 2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical Int. J. Pharm. 375 1-2 2009 75 83
143. 2A and DOTA chelation systems J. Nucl. Med. 48 8 2007 1327 1337
144. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma Nucl. Med. Biol. 33 3 2006 371 380
145. Honer, M., L. Mu, T. Stellfeld, K. Graham, M. Martic, C.R. Fischer, L. Lehmann, P.A. Schubiger, S.M. Ametamey, L. Dinkelborg, A. Srinivasan, and S. Borkowski 18 F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors J Nucl Med. 52 2 2011 270-8
146. U.H. Weidle, W. Scheuer, D. Eggle, S. Klostermann, and H. Stockinger Cancer-related issues of CD147 Cancer Genomics Proteomics 7 3 2010 157 169
147. K. Nabeshima, H. Iwasaki, K. Koga, H. Hojo, J. Suzumiya, and M. Kikuchi Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression Pathol. Int. 56 7 2006 359 367
148. J. Hao, M.C. Madigan, A. Khatri, C.A. Power, T.T. Hung, J. Beretov, L. Chang, W. Xiao, P.J. Cozzi, P.H. Graham, J.H. Kearsley, and Y. Li In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147 PLoS ONE 7 8 2012 e40716
149. D. Naor, S.B. Wallach-Dayan, M.A. Zahalka, and R.V. Sionov Involvement of CD44, a molecule with a thousand faces, in cancer dissemination Semin. Cancer Biol. 18 4 2008 260 267
150. H. Ponta, L. Sherman, and P.A. Herrlich CD44: from adhesion molecules to signalling regulators Nat. Rev. Mol. Cell Biol. 4 1 2003 33 45
151. W.D. Zhong, Z.D. Han, H.C. He, X.C. Bi, Q.S. Dai, G. Zhu, Y.K. Ye, Y.X. Liang, W.J. Qin, Z. Zhang, G.H. Zeng, and Z.N. Chen CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer Oncology 75 3-4 2008 230 236
152. J. Sun, and M.E. Hemler Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions Cancer Res. 61 5 2001 2276 2281
153. S. Riethdorf, N. Reimers, V. Assmann, J.W. Kornfeld, L. Terracciano, G. Sauter, and K. Pantel High incidence of EMMPRIN expression in human tumors Int. J. Cancer 119 8 2006 1800 1810
154. N. Tsuchiya, S. Narita, T. Kumazawa, T. Inoue, Z. Ma, H. Tsuruta, M. Saito, Y. Horikawa, T. Yuasa, S. Satoh, O. Ogawa, and T. Habuchi Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer Oncol. Rep. 22 3 2009 493 499
155. D. Millimaggi, M. Mari, S. D'Ascenzo, E. Carosa, E.A. Jannini, S. Zucker, G. Carta, A. Pavan, and V. Dolo Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells Neoplasia 9 4 2007 349 357
156. S.S. Sidhu, A.T. Mengistab, A.N. Tauscher, J. LaVail, and C. Basbaum The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions Oncogene 23 4 2004 956 963
157. E.E. Gabison, T. Hoang-Xuan, A. Mauviel, and S. Menashi EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair Biochimie 87 3-4 2005 361 368
158. Zhu, H., J. Zhao, B. Zhu, J. Collazo, J. Gal, P. Shi, L. Liu, A.L. Strom, X. Lu, R.O. McCann, M. Toborek, and N. Kyprianou EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer Prostate. 72 1 2012 72 81
159. T. Muramatsu, and T. Miyauchi Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion Histol. Histopathol. 18 3 2003 981 987
160. Hao, J.L., P.J. Cozzi, A. Khatri, C.A. Power, and Y. Li CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer Curr Cancer Drug Targets. 10 3 2010 287 306
161. Z.D. Han, X.C. Bi, W.J. Qin, H.C. He, Q.S. Dai, J. Zou, Y.K. Ye, Y.X. Liang, G.H. Zeng, Z.N. Chen, and W.D. Zhong CD147 expression indicates unfavourable prognosis in prostate cancer Pathol. Oncol. Res. 15 3 2009 369 374
162. W.D. Zhong, Y.X. Liang, S.X. Lin, L. Li, H.C. He, X.C. Bi, Z.D. Han, Q.S. Dai, Y.K. Ye, Q.B. Chen, Y.S. Wang, G.H. Zeng, G. Zhu, Z. Zhang, Z.N. Chen, and C.L. Wu Expression of CD147 is associated with prostate cancer progression Int. J. Cancer 130 2 2012 300 308
163. Matsudaira, H., T. Asakura, K. Aoki, Y. Searashi, T. Matsuura, H. Nakajima, H. Tajiri, and K. Ohkawa Target chemotherapy of anti-CD14 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells Int J Oncol. 36 1 2010 77 83
164. L. Sweeny, Y.E. Hartman, K.R. Zinn, J.R. Prudent, D.J. Marshall, M.S. Shekhani, and E.L. Rosenthal A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma Oral Oncol. 49 10 2013 991 997
165. D. Maetzel, S. Denzel, B. Mack, M. Canis, P. Went, M. Benk, C. Kieu, P. Papior, P.A. Baeuerle, M. Munz, and O. Gires Nuclear signalling by tumour-associated antigen EpCAM Nat. Cell Biol. 11 2 2009 162 171
166. M. Trzpis, P.M. McLaughlin, L.M. de Leij, and M.C. Harmsen Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule Am. J. Pathol. 171 2 2007 386 395
167. C. Patriarca, R.M. Macchi, A.K. Marschner, and H. Mellstedt Epithelial cell adhesion molecule expression (CD326) in cancer: a short review Cancer Treat. Rev. 38 1 2012 68 75
168. J. Ni, P. Cozzi, J. Hao, J. Beretov, L. Chang, W. Duan, S. Shigdar, W. Delprado, P. Graham, J. Bucci, J. Kearsley, and Y. Li Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway Int. J. Biochem. Cell Biol. 45 12 2013 2736 2748
169. P. Went, M. Vasei, L. Bubendorf, L. Terracciano, L. Tornillo, U. Riede, J. Kononen, R. Simon, G. Sauter, and P.A. Baeuerle Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers Br. J. Cancer 94 1 2006 128 135
170. P.T. Went, A. Lugli, S. Meier, M. Bundi, M. Mirlacher, G. Sauter, and S. Dirnhofer Frequent EpCam protein expression in human carcinomas Hum. Pathol. 35 1 2004 122 128
171. Ni, J., P.J. Cozzi, W. Duan, S. Shigdar, P.H. Graham, K.H. John, and Y. Li Role of the EpCAM (CD326) in prostate cancer metastasis and progression Cancer Metastasis Rev. 31 3-4 2012 779-91
172. Benko, G., B. Spajic, B. Kruslin, and D. Tomas, Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 31(4): p. 468-74.
173. A. Datta-Mannan, D.R. Witcher, Y. Tang, J. Watkins, and V.J. Wroblewski Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor J. Biol. Chem. 282 3 2007 1709 1717
174. C.G. Rao, D. Chianese, G.V. Doyle, M.C. Miller, T. Russell, R.A. Sanders Jr., and L.W. Terstappen Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors Int. J. Oncol. 27 1 2005 49 57
175. S. Mukherjee, A.M. Richardson, J. Rodriguez-Canales, K. Ylaya, H.S. Erickson, A. Player, E.S. Kawasaki, P.A. Pinto, P.L. Choyke, M.J. Merino, P.S. Albert, R.F. Chuaqui, and M.R. Emmert-Buck Identification of EpCAM as a molecular target of prostate cancer stroma Am. J. Pathol. 175 6 2009 2277 2287
176. M. Mitra, M. Kandalam, J. Rangasamy, B. Shankar, U.K. Maheswari, S. Swaminathan, and S. Krishnakumar Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells Mol. Vis. 19 2013 1029 1038
177. L. Patrawala, T. Calhoun, R. Schneider-Broussard, H. Li, B. Bhatia, S. Tang, J.G. Reilly, D. Chandra, J. Zhou, K. Claypool, L. Coghlan, and D.G. Tang Highly purified CD44 + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells Oncogene 25 12 2006 1696 1708
178. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, and N.J. Maitland Prospective identification of tumorigenic prostate cancer stem cells Cancer Res. 65 23 2005 10946 10951
179. N. Subramanian, V. Raghunathan, J.R. Kanwar, R.K. Kanwar, S.V. Elchuri, V. Khetan, and S. Krishnakumar Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer Mol. Vis. 18 2012 2783 2795
180. M. Mitra, R. Misra, A. Harilal, S.K. Sahoo, and S. Krishnakumar Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells Mol. Vis. 17 2011 2724 2737
181. G. Moldenhauer, A.V. Salnikov, S. Luttgau, I. Herr, J. Anderl, and H. Faulstich Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma J. Natl. Cancer Inst. 104 8 2012 622 634
182. N. Marschner, D. Ruttinger, G. Zugmaier, G. Nemere, J. Lehmann, P. Obrist, P.A. Baeuerle, A. Wolf, M. Schmidt, P.A. Abrahamsson, C. Reinhardt, and A. Heidenreich Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy Urol. Int. 85 4 2010 386 395
183. A. Aguilar-Rojas, and M. Huerta-Reyes Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review) Oncol. Rep. 22 5 2009 981 990
184. A.V. Schally, and A. Nagy New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin Life Sci. 72 21 2003 2305 2320
185. P. Limonta, R.M. Moretti, M.M. Marelli, D. Dondi, M. Parenti, and M. Motta The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway Endocrinology 140 11 1999 5250 5256
186. Y. Tolkach, S. Joniau, and H. Van Poppel Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? BJU Int. 111 7 2013 1021 1030
187. A. Tieva, P. Stattin, P. Wikstrom, A. Bergh, and J.E. Damber Gonadotropin-releasing hormone receptor expression in the human prostate Prostate 47 4 2001 276 284
188. G. Halmos, J.M. Arencibia, A.V. Schally, R. Davis, and D.G. Bostwick High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers J. Urol. 163 2 2000 623 629
189. S.V. Liu, S. Liu, and J. Pinski Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer Expert Opin. Investig. Drugs 20 6 2011 769 778
190. A. Nagy, and A.V. Schally Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers Biol. Reprod. 73 5 2005 851 859
191. B. Straub, M. Muller, H. Krause, M. Schrader, C. Goessl, R. Heicappell, and K. Miller Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers Clin. Cancer Res. 7 8 2001 2340 2343
192. S. Bajusz, T. Janaky, V.J. Csernus, L. Bokser, M. Fekete, G. Srkalovic, T.W. Redding, and A.V. Schally Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6 Proc. Natl. Acad. Sci. U. S. A. 86 16 1989 6318 6322
193. J. Pinski, A.V. Schally, T. Yano, K. Szepeshazi, G. Halmos, K. Groot, A.M. Comaru-Schally, S. Radulovic, and A. Nagy Inhibition of growth of experimental prostate cancer in rats by LH - RH analogs linked to cytotoxic radicals Prostate 23 2 1993 165 178
194. M. Letsch, A.V. Schally, K. Szepeshazi, G. Halmos, and A. Nagy Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers Clin. Cancer Res. 9 12 2003 4505 4513
195. J. Engel, G. Emons, J. Pinski, and A.V. Schally AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors Expert Opin. Investig. Drugs 21 6 2012 891 899
196. S. Sundaram, C. Durairaj, R. Kadam, and U.B. Kompella Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy Mol. Cancer Ther. 8 6 2009 1655 1665
197. Z. Nahleh, A. Tfayli, A. Najm, A. El Sayed, and Z. Nahle Heat shock proteins in cancer: targeting the 'chaperones' Futur. Med. Chem. 4 7 2012 927 935
198. L.S. Kim, and J.H. Kim Heat shock protein as molecular targets for breast cancer therapeutics J. Breast Cancer 14 3 2011 167 174
199. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat. Rev. Cancer 5 10 2005 761 772
200. Tutar, L., and Y. Tutar Heat shock proteins; an overview Curr Pharm Biotechnol. 11 2 2010 216-22
201. S. Walter, and J. Buchner Molecular chaperones - cellular machines for protein folding Angew. Chem. Int. Ed. Engl. 41 7 2002 1098 1113
202. A. Mathew, and R.I. Morimoto Role of the heat-shock response in the life and death of proteins Ann. N. Y. Acad. Sci. 851 1998 99 111
203. W. Hessenkemper, and A. Baniahmad Targeting heat shock proteins in prostate cancer Curr. Med. Chem. 20 22 2013 2731 2740
204. A. Parcellier, S. Gurbuxani, E. Schmitt, E. Solary, and C. Garrido Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways Biochem. Biophys. Res. Commun. 304 3 2003 505 512
205. C.G. Concannon, S. Orrenius, and A. Samali Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c Gene Expr. 9 4-5 2001 195 201
206. G.B. Schneider, H. Hamano, and L.F. Cooper In vivo evaluation of hsp27 as an inhibitor of actin polymerization: hsp27 limits actin stress fiber and focal adhesion formation after heat shock J. Cell. Physiol. 177 4 1998 575 584
207. G. Jego, A. Hazoume, R. Seigneuric, and C. Garrido Targeting heat shock proteins in cancer Cancer Lett. 332 2 2013 275 285
208. L.M. Hendershot, V.A. Valentine, A.S. Lee, S.W. Morris, and D.N. Shapiro Localization of the gene encoding human BiP/GRP78, the endoplasmic reticulum cognate of the HSP70 family, to chromosome 9q34 Genomics 20 2 1994 281 284
209. R. Sarkars, S. Mukherjee, and M. Roy Targeting heat shock proteins by phenethyl isothiocyanate results in cell-cycle arrest and apoptosis of human breast cancer cells Nutr. Cancer 65 3 2013 480 493
210. D. Tang, M.A. Khaleque, E.L. Jones, J.R. Theriault, C. Li, W.H. Wong, M.A. Stevenson, and S.K. Calderwood Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo Cell Stress Chaperones 10 1 2005 46 58
211. P. Rocchi, E. Beraldi, S. Ettinger, L. Fazli, R.L. Vessella, C. Nelson, and M. Gleave Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis Cancer Res. 65 23 2005 11083 11093
212. P. Rocchi, A. So, S. Kojima, M. Signaevsky, E. Beraldi, L. Fazli, A. Hurtado-Coll, K. Yamanaka, and M. Gleave Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer Cancer Res. 64 18 2004 6595 6602
213. P.A. Cornford, A.R. Dodson, K.F. Parsons, A.D. Desmond, A. Woolfenden, M. Fordham, J.P. Neoptolemos, Y. Ke, and C.S. Foster Heat shock protein expression independently predicts clinical outcome in prostate cancer Cancer Res. 60 24 2000 7099 7105
214. L. Pootrakul, R.H. Datar, S.R. Shi, J. Cai, D. Hawes, S.G. Groshen, A.S. Lee, and R.J. Cote Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer Clin. Cancer Res. 12 20 Pt 1 2006 5987 5993
215. Xu, W., L. Liu, N.J. Brown, S. Christian, and D. Hornby Quantum dot-conjugated anti-GRP78 scFv inhibits cancer growth in mice Molecules. 17 1 2012 796 808
216. M.A. Arap, J. Lahdenranta, P.J. Mintz, A. Hajitou, A.S. Sarkis, W. Arap, and R. Pasqualini Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands Cancer Cell 6 3 2004 275 284
217. N. Larson, A. Gormley, N. Frazier, and H. Ghandehari Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia J. Control. Release 170 1 2013 41 50
218. A.J. Gormley, N. Larson, S. Sadekar, R. Robinson, A. Ray, and H. Ghandehari Guided delivery of polymer therapeutics using plasmonic photothermal therapy Nano Today 7 3 2012 158 167
219. N. Larson, A. Ray, A. Malugin, D.B. Pike, and H. Ghandehari HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer Pharm. Res. 27 12 2010 2683 2693
220. R. Mahato, W. Tai, and K. Cheng Prodrugs for improving tumor targetability and efficiency Adv. Drug Deliv. Rev. 63 8 2011 659 670
221. G.M. Yousef, and E.P. Diamandis The new human tissue kallikrein gene family: structure, function, and association to disease Endocr. Rev. 22 2 2001 184 204
222. J. Lovgren, K. Rajakoski, M. Karp, a. Lundwall, and H. Lilja Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2 Biochem. Biophys. Res. Commun. 238 2 1997 549 555
223. A. Christensson, C.B. Laurell, and H. Lilja Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors Eur. J. Biochem. 194 3 1990 755 763
224. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate-specific antigen J. Clin. Oncol. 21 2 2003 383 391
225. K.C. Cary, and M.R. Cooperberg Biomarkers in prostate cancer surveillance and screening: past, present, and future Ther. Adv. Urol. 5 6 2013 318 329
226. S.R. Denmeade, W. Lou, J. Lovgren, J. Malm, H. Lilja, and J.T. Isaacs Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen Cancer Res. 57 21 1997 4924 4930
227. S.R. Denmeade, A. Nagy, J. Gao, H. Lilja, A.V. Schally, and J.T. Isaacs Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen Cancer Res. 58 12 1998 2537 2540
228. S.S. Chandran, A. Nan, D.M. Rosen, H. Ghandehari, and S.R. Denmeade A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer Mol. Cancer Ther. 6 11 2007 2928 2937
229. D. DeFeo-Jones, V.M. Garsky, B.K. Wong, D.M. Feng, T. Bolyar, K. Haskell, D.M. Kiefer, K. Leander, E. McAvoy, P. Lumma, J. Wai, E.T. Senderak, S.L. Motzel, K. Keenan, M. Van Zwieten, J.H. Lin, R. Freidinger, J. Huff, A. Oliff, and R.E. Jones A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nat. Med. 6 11 2000 1248 1252
230. D.C. Yu, Y. Chen, M. Seng, J. Dilley, and D.R. Henderson The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res. 59 17 1999 4200 4203
231. K.Y. Choi, G. Saravanakumar, J.H. Park, and K. Park Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer Colloids Surf. B: Biointerfaces 99 2012 82 94
232. M.M. Mohamed, and B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat. Rev. Cancer 6 10 2006 764 775
233. G.J. Tan, Z.K. Peng, J.P. Lu, and F.Q. Tang Cathepsins mediate tumor metastasis World J. Biol. Chem. 4 4 2013 91 101
234. V. Turk, B. Turk, and D. Turk Lysosomal cysteine proteases: facts and opportunities EMBO J. 20 17 2001 4629 4633
235. P.L. Fernandez, X. Farre, A. Nadal, E. Fernandez, N. Peiro, B.F. Sloane, G.P. Shi, H.A. Chapman, E. Campo, and A. Cardesa Expression of cathepsins B and S in the progression of prostate carcinoma Int. J. Cancer 95 1 2001 51 55
236. K.D. Brubaker, R.L. Vessella, L.D. True, R. Thomas, and E. Corey Cathepsin K mRNA and protein expression in prostate cancer progression J. Bone Miner. Res. 18 2 2003 222 230
237. A. Waghray, D. Keppler, B.F. Sloane, L. Schuger, and Y.Q. Chen Analysis of a truncated form of cathepsin H in human prostate tumor cells J. Biol. Chem. 277 13 2002 11533 11538
238. P.M. Loadman, M.C. Bibby, J.A. Double, W.M. Al-Shakhaa, and R. Duncan Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1 Clin. Cancer Res. 5 11 1999 3682 3688
239. A. Page-McCaw, A.J. Ewald, and Z. Werb Matrix metalloproteinases and the regulation of tissue remodelling Nat. Rev. Mol. Cell Biol. 8 3 2007 221 233
240. I. Massova, L.P. Kotra, R. Fridman, and S. Mobashery Matrix metalloproteinases: structures, evolution, and diversification FASEB J. 12 12 1998 1075 1095
241. F. Ozden, C. Saygin, D. Uzunaslan, B. Onal, H. Durak, and H. Aki Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival J. Cancer Res. Clin. Oncol. 139 8 2013 1373 1382
242. S. Escaff, J.M. Fernandez, L.O. Gonzalez, A. Suarez, S. Gonzalez-Reyes, J.M. Gonzalez, and F.J. Vizoso Study of matrix metalloproteinases and their inhibitors in prostate cancer Br. J. Cancer 102 5 2010 922 929
243. R. Visse, and H. Nagase Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ. Res. 92 8 2003 827 839
244. B. Brehmer, S. Biesterfeld, and G. Jakse Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue Prostate Cancer Prostatic Dis. 6 3 2003 217 222
245. M. Wood, K. Fudge, J.L. Mohler, A.R. Frost, F. Garcia, M. Wang, and M.E. Stearns In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer Clin. Exp. Metastasis 15 3 1997 246 258
246. M.E. Stearns, K. Fudge, F. Garcia, and M. Wang IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression Invasion Metastasis 17 2 1997 62 74
247. K. Jung, L. Nowak, M. Lein, F. Priem, D. Schnorr, and S.A. Loening Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer Int. J. Cancer 74 2 1997 220 223
248. T. Terada, M. Iwai, S. Kawakami, F. Yamashita, and M. Hashida Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting J. Control. Release 111 3 2006 333 342
249. G. Gu, H. Xia, Q. Hu, Z. Liu, M. Jiang, T. Kang, D. Miao, Y. Tu, Z. Pang, Q. Song, L. Yao, H. Chen, X. Gao, and J. Chen PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy Biomaterials 34 1 2013 196 208
250. F.G. Giancotti, and G. Tarone Positional control of cell fate through joint integrin/receptor protein kinase signaling Annu. Rev. Cell Dev. Biol. 19 2003 173 206
251. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 285 5430 1999 1028 1032
252. H. Jin, and J. Varner Integrins: roles in cancer development and as treatment targets Br. J. Cancer 90 3 2004 561 565
253. H.L. Goel, J. Li, S. Kogan, and L.R. Languino Integrins in prostate cancer progression Endocr. Relat. Cancer 15 3 2008 657 664
254. M. Sutherland, A. Gordon, S.D. Shnyder, L.H. Patterson, and H.M. Sheldrake RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis Cancers (Basel) 4 4 2012 1106 1145
255. D.Q. Zheng, A.S. Woodard, M. Fornaro, G. Tallini, and L.R. Languino Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway Cancer Res. 59 7 1999 1655 1664
256. N. Graf, D.R. Bielenberg, N. Kolishetti, C. Muus, J. Banyard, O.C. Farokhzad, and S.J. Lippard alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug ACS Nano 6 5 2012 4530 4539
257. F. Danhier, B. Vroman, N. Lecouturier, N. Crokart, V. Pourcelle, H. Freichels, C. Jerome, J. Marchand-Brynaert, O. Feron, and V. Preat Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel J. Control. Release 140 2 2009 166 173
258. Z.B. Li, Z. Wu, K. Chen, E.K. Ryu, and X. Chen 18 F-labeled BBN-RGD heterodimer for prostate cancer imaging J. Nucl. Med. 49 3 2008 453 461
259. A. Musiyenko, V. Bitko, and S. Barik Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells J. Mol. Med. (Berl) 86 3 2008 313 322
260. L. Campagnolo, A. Leahy, S. Chitnis, S. Koschnick, M.J. Fitch, J.T. Fallon, D. Loskutoff, M.B. Taubman, and H. Stuhlmann EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury Am. J. Pathol. 167 1 2005 275 284
261. M.J. Fitch, L. Campagnolo, F. Kuhnert, and H. Stuhlmann Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells Dev. Dyn. 230 2 2004 316 324
262. L.H. Parker, M. Schmidt, S.W. Jin, A.M. Gray, D. Beis, T. Pham, G. Frantz, S. Palmieri, K. Hillan, D.Y. Stainier, F.J. De Sauvage, and W. Ye The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation Nature 428 6984 2004 754 758
263. B.L. Hogan, and P.A. Kolodziej Organogenesis: molecular mechanisms of tubulogenesis Nat. Rev. Genet. 3 7 2002 513 523
264. G. Philippin-Lauridant, M.C. Baranzelli, C. Samson, C. Fournier, S. Pinte, V. Mattot, J. Bonneterre, and F. Soncin Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer Int. J. Oncol. 42 4 2013 1367 1375
265. C. Fan, L.Y. Yang, F. Wu, Y.M. Tao, L.S. Liu, J.F. Zhang, Y.N. He, L.L. Tang, G.D. Chen, and L. Guo The expression of Egfl7 in human normal tissues and epithelial tumors Int. J. Biol. Markers 28 1 2013 71 83
266. Y. Ling, K. Wei, Y. Luo, X. Gao, and S. Zhong Dual docetaxel/ superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy Biomaterials 32 29 2011 7139 7150
267. S.M. Okarvi, and I. Al Jammaz Synthesis and evaluation of a technetium-99 m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors Nucl. Med. Biol. 37 3 2010 277 288
268. A. Accardo, G. Salsano, A. Morisco, M. Aurilio, A. Parisi, F. Maione, C. Cicala, D. Tesauro, L. Aloj, G. De Rosa, and G. Morelli Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent Int. J. Nanomedicine 7 2012 2007 2017
269. R. Sangha, and C. Butts L-BLP25: a peptide vaccine strategy in non small cell lung cancer Clin. Cancer Res. 13 15 Pt 2 2007 s4652 s4654